FDA
-
-
-
-
-
-
-
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
-
-
-
-
-
-
-
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
-
-
-
-
-
-
-
Immune Design (IMDZ) Reports Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
-
-
-
-
-
-
-
Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting
-
-
-
-
322,224 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

